Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keats

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
Cancer Cell|September 14, 2013
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myelomaChungyee Leung-Hagesteijn, Natalie Erdmann, Grace Cheung, et al.
Cancer Cell|August 31, 2017
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple MyelomaChungyee Leung-Hagesteijn, Natalie Erdmann, Grace Cheung, et al.
Blood|October 24, 2002
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionJonathan J Keats, Tony Reiman, Christopher A Maxwell, et al.
American Journal of Human Genetics|October 30, 2004
Chronic and recurrent otitis media: a genome scan for susceptibility lociKathleen A Daly, W Mark Brown, Fernando Segade, et al.
Nature Immunology|November 11, 2008
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signalingSivakumar Vallabhapurapu, Atsushi Matsuzawa, Weizhou Zhang, et al.
Leukemia|March 12, 2010
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myelomaW J Chng, M A Gertz, T-H Chung, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 15, 2005
SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCsBrian J Taylor, Tony Reiman, Julie A Pittman, et al.
British Journal of Haematology|December 14, 2007
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myelomaRobert P Evans, Claudia Naber, Tara Steffler, et al.
Blood|December 20, 2008
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivoRodger E Tiedemann, Jessica Schmidt, Jonathan J Keats, et al.
Human Mutation|January 1, 1997
Norrie disease gene mutation in a large Costa Rican kindred with a novel phenotype including venous insufficiencyH L Rehm, G A Gutiérrez-Espeleta, R Garcia, et al.
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
Cancer Cell|September 14, 2013
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myelomaChungyee Leung-Hagesteijn, Natalie Erdmann, Grace Cheung, et al.
Cancer Cell|August 31, 2017
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple MyelomaChungyee Leung-Hagesteijn, Natalie Erdmann, Grace Cheung, et al.
Blood|October 24, 2002
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionJonathan J Keats, Tony Reiman, Christopher A Maxwell, et al.
American Journal of Human Genetics|October 30, 2004
Chronic and recurrent otitis media: a genome scan for susceptibility lociKathleen A Daly, W Mark Brown, Fernando Segade, et al.
Nature Immunology|November 11, 2008
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signalingSivakumar Vallabhapurapu, Atsushi Matsuzawa, Weizhou Zhang, et al.
Leukemia|March 12, 2010
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myelomaW J Chng, M A Gertz, T-H Chung, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 15, 2005
SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCsBrian J Taylor, Tony Reiman, Julie A Pittman, et al.
British Journal of Haematology|December 14, 2007
The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myelomaRobert P Evans, Claudia Naber, Tara Steffler, et al.
Blood|December 20, 2008
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivoRodger E Tiedemann, Jessica Schmidt, Jonathan J Keats, et al.
Human Mutation|January 1, 1997
Norrie disease gene mutation in a large Costa Rican kindred with a novel phenotype including venous insufficiencyH L Rehm, G A Gutiérrez-Espeleta, R Garcia, et al.
Pageof 15